高通量血液透析终末期肾病患者口服瑞舒伐他

发布时间：2018-01-31 01:54

本文关键词： 瑞舒伐他汀辛伐他汀超敏C反应蛋白肿瘤坏死因子α 白细胞介素总胆固醇甘油三酯低密度脂蛋白胆固醇高密度脂蛋白胆固醇　出处：《山东医药》2017年31期 　论文类型：期刊论文

【摘要】：目的比较高通量血液透析终末期肾病患者口服瑞舒伐他汀、辛伐他汀后血清炎症因子和血脂水平变化。方法 78例终末期肾病患者随机分为瑞舒伐他汀组40例与辛伐他汀组38例,两组均接受高通量血液透析,瑞舒伐他汀组在此基础上口服瑞舒伐他汀,辛伐他汀组在此基础上口服辛伐他汀,比较两组血清炎症因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)]及血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]。结果与辛伐他汀组比较,瑞舒伐他汀组治疗后血清hs-CRP、IL-6、TNF-α水平降低(P均0.05);与同组治疗前比较,两组治疗后hs-CRP、IL-6、TNF-α水平降低(P均0.05)。与辛伐他汀组比较,瑞舒伐他汀组治疗后LDL-C水平降低(P0.05);与同组治疗前比较,两组治疗后TC、TG、LDL-C水平降低,HDL-C水平升高(P均0.05)。结论瑞舒伐他汀、辛伐他汀均能降低血清hs-CRP、TNF-α、IL-6及TC、TG水平,升高LDL-C水平,但瑞舒伐他汀效果更佳。
[Abstract]:Objective to compare the efficacy of oral resuvastatin in patients with end-stage renal disease after high-throughput hemodialysis. Methods Seventy-eight patients with end-stage nephropathy were randomly divided into rosuvastatin group (n = 40) and simvastatin group (n = 38). The serum inflammatory factors were compared between the rosuvastatin group and simvastatin group. [Hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor- 伪 (TNF- 伪), interleukin-6 (IL-6) and serum lipids. [Total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were compared with simvastatin group. After treatment, the serum levels of hs-CRP IL-6 and TNF- 伪 decreased by 0.05 渭 g / L in the recuvastatin group. Compared with the same group before treatment, the level of hs-CRPnIL-6TNF- 伪 decreased by 0.05 and compared with simvastatin group. After treatment, the level of LDL-C decreased in Risuvastatin group (P 0.05). Compared with the same group before treatment, the level of TCU TGN LDL-C decreased and HDL-C increased in both groups (P < 0.05). Simvastatin could decrease the serum levels of hs-CRP- 伪 TNF- 伪 and TG and increase the level of LDL-C, but the effect of rosuvastatin was better.
【作者单位】：华中科技大学同济医学院附属武汉中心医院;长春中医药大学附属医院;
【基金】：国家自然科学基金青年基金资助项目(81400734) 湖北省科技厅基金资助项目(2015CFB241) 武汉市卫计委基金资助项目(WZ13D08)
【分类号】：R692.5
【正文快照】： 终末期肾病是慢性肾病晚期共有的临床综合征,其肾小球滤过率下降,诸如尿酸、血脂、电解质代谢紊乱,进而引起高血脂血症、高尿酸血症、高磷血症等。维持性血液透析是治疗终末期肾病的主要技术,包括低通量血液透析、高通量血液透析(HFHD)和联机血液透析滤过,80%的患者需要依靠

【相似文献】